While the results of the INVICTUS trial could not confirm the efficacy of ripretinib in KIT/PDGFRA wild-type GIST in the fourth line or beyond, the preclinical analysis does show potential efficacy [89]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.